Explore the Impacts of One Session Theta Burst Stimulation Over Cerebellum in Adults With Autism Spectrum Disorder
Primary Purpose
Autism Spectrum Disorder
Status
Active
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
intermittent theta burst stimulation
Sponsored by
About this trial
This is an interventional treatment trial for Autism Spectrum Disorder
Eligibility Criteria
Inclusion Criteria:
- Adults with autism spectrum disorder (≥18 years old), confirmed by Autism Diagnostic Observation Schedule.
Exclusion Criteria:
- Previous or current severe neurological disorder such as epilepsy, visual or hearing impairment.
- Previous or current severe systemic disease such as cardiovascular disease, diabetes or infection.
- Previous or current severe brain injury
- Implementation of metal materials such as pacemaker or medication pump
- Previous or current severe psychiatric disorders such as schizophrenia, bipolar disorder or substance abuse
- Pregnancy
- Individuals with a significant brain abnormality such as intracranial space occupied lesions
- History of brain surgery or nervous system infection, such as meningitis and encephalitis
- Concurrent use of medications which increased the risk of seizure attack
- Participate another clinical trial within one month
- Skin trauma on application site
- Individuals suffering from multiple sclerosis
- Individuals with a large ischemic scar
- Individuals suffering from sleep deprivation during rTMS procedures
- Individuals with a heavy consumption of alcohol
- Current taking antiepileptic drugs
- Individuals with a migraine headache from increased intracranial pressure
- Unable to complete MRI scan
Withdrawal criteria:
- Seizure attack during study period
- Autistic symptoms worsened obviously during study period
- Extreme agitation or irritability during study period
- Participants request
- Take antiepileptic drug during study period
Sites / Locations
- Chang Gung Memorial Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Active
Arm Description
All of the participants will accept one session iTBS over right Crus I/II. The total pulses of every session are 1200 pulses (600 pulses with 15 minutes interval) *iTBS = intermittent theta burst stimulation.
Outcomes
Primary Outcome Measures
Adverse effects report form (Headache)
Recording adverse effects in participants after iTBS.
Adverse effects report form (Dizziness)
Recording adverse effects in participants after iTBS.
Adverse effects report form (Tinnitus)
Recording adverse effects in participants after iTBS.
Adverse effects report form (Seizure)
Recording adverse effects in participants after iTBS.
Adverse effects report form (Other)
Recording adverse effects in participants after iTBS.
Secondary Outcome Measures
MRI T1
Brain structural volumes (cm²)
functional MRI (resting-state/biological motion task) - BOLD signal
Blood-oxygen-level-dependent (BOLD) signal is a measurement used in fMRI, which reflects the neural activity.
Full Information
NCT ID
NCT05578261
First Posted
October 11, 2022
Last Updated
August 29, 2023
Sponsor
Chang Gung Memorial Hospital
1. Study Identification
Unique Protocol Identification Number
NCT05578261
Brief Title
Explore the Impacts of One Session Theta Burst Stimulation Over Cerebellum in Adults With Autism Spectrum Disorder
Official Title
Explore the Impacts of One Session Theta Burst Stimulation Over Cerebellum in Adults With Autism Spectrum Disorder
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
December 28, 2022 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chang Gung Memorial Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
The investigator would like to investigate the impact of theta-burst stimulation over cerebellum in adults with autism spectrum disorder
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Autism Spectrum Disorder
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Active
Arm Type
Experimental
Arm Description
All of the participants will accept one session iTBS over right Crus I/II. The total pulses of every session are 1200 pulses (600 pulses with 15 minutes interval)
*iTBS = intermittent theta burst stimulation.
Intervention Type
Device
Intervention Name(s)
intermittent theta burst stimulation
Intervention Description
stimulatory protocol
Primary Outcome Measure Information:
Title
Adverse effects report form (Headache)
Description
Recording adverse effects in participants after iTBS.
Time Frame
1 week after iTBS (post iTBS)
Title
Adverse effects report form (Dizziness)
Description
Recording adverse effects in participants after iTBS.
Time Frame
1 week after iTBS (post iTBS)
Title
Adverse effects report form (Tinnitus)
Description
Recording adverse effects in participants after iTBS.
Time Frame
1 week after iTBS (post iTBS)
Title
Adverse effects report form (Seizure)
Description
Recording adverse effects in participants after iTBS.
Time Frame
1 week after iTBS (post iTBS)
Title
Adverse effects report form (Other)
Description
Recording adverse effects in participants after iTBS.
Time Frame
1 week after iTBS (post iTBS)
Secondary Outcome Measure Information:
Title
MRI T1
Description
Brain structural volumes (cm²)
Time Frame
Within one month
Title
functional MRI (resting-state/biological motion task) - BOLD signal
Description
Blood-oxygen-level-dependent (BOLD) signal is a measurement used in fMRI, which reflects the neural activity.
Time Frame
Within one month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adults with autism spectrum disorder (≥18 years old), confirmed by Autism Diagnostic Observation Schedule.
Exclusion Criteria:
Previous or current severe neurological disorder such as epilepsy, visual or hearing impairment.
Previous or current severe systemic disease such as cardiovascular disease, diabetes or infection.
Previous or current severe brain injury
Implementation of metal materials such as pacemaker or medication pump
Previous or current severe psychiatric disorders such as schizophrenia, bipolar disorder or substance abuse
Pregnancy
Individuals with a significant brain abnormality such as intracranial space occupied lesions
History of brain surgery or nervous system infection, such as meningitis and encephalitis
Concurrent use of medications which increased the risk of seizure attack
Participate another clinical trial within one month
Skin trauma on application site
Individuals suffering from multiple sclerosis
Individuals with a large ischemic scar
Individuals suffering from sleep deprivation during rTMS procedures
Individuals with a heavy consumption of alcohol
Current taking antiepileptic drugs
Individuals with a migraine headache from increased intracranial pressure
Unable to complete MRI scan
Withdrawal criteria:
Seizure attack during study period
Autistic symptoms worsened obviously during study period
Extreme agitation or irritability during study period
Participants request
Take antiepileptic drug during study period
Facility Information:
Facility Name
Chang Gung Memorial Hospital
City
Taoyuan
Country
Taiwan
12. IPD Sharing Statement
Learn more about this trial
Explore the Impacts of One Session Theta Burst Stimulation Over Cerebellum in Adults With Autism Spectrum Disorder
We'll reach out to this number within 24 hrs